ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

MENLO PARK, Calif. and SINGAPORE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Pte Ltd (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts showcasing new translational data on eblasakimab have been accepted as late-breaking e-posters at the 51^st Annual European Society for Dermatological Research (ESDR) Meeting, taking place from September 28 to October 1, 2022, in Amsterdam, Netherlands.

51^st Annual European Society for Dermatological Research e-poster details

Poster 1: Spatial localization and functional role of IL-13Rα1 signaling in atopic dermatitis
(abstract ID: LB060)

Poster 2:Insight into novel itch pathways and spontaneous neuronal activity by targeting interleukin-13 receptor alpha 1 (IL-13Rα1) with eblasakimab
(abstract ID: LB061)

Poster availability date: Wednesday, September 28, 2022.

The posters will be available to view online in the Investor Relations section of ASLAN’s website following presentation: https://ir.aslanpharma.com/.

About eblasakimab

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for atopic dermatitis patients. In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD. In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab (also known as ASLAN004), a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

Media and IR contacts